{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:27:42Z","timestamp":1786663662781,"version":"build-2736575974"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"First Affiliated Hospital of Zhejiang University","award":["2023ZYHL23"],"award-info":[{"award-number":["2023ZYHL23"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-026-00882-5","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T02:07:26Z","timestamp":1780970846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging strategies in venous thromboembolism: a narrative review of pharmacological innovations"],"prefix":"10.1186","volume":"24","author":[{"given":"Juan","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1641-1472","authenticated-orcid":false,"given":"Kun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"882_CR1","doi-asserted-by":"crossref","unstructured":"Kahn SR. The post-thrombotic syndrome. Hematol Am Soc Hematol Educ Program. 2016;413\u20138.","DOI":"10.1182\/asheducation-2016.1.413"},{"key":"882_CR2","doi-asserted-by":"publisher","unstructured":"Shah KP, Lee C, McBane RD, Piazza G, Frantz RP, Houghton DE et al. Post\u2013pulmonary embolism syndrome\u2014a diagnostic dilemma and challenging management. Mayo Clin Proc. Mayo Foundation for Medical Education and Research; 2024;99:1965\u201382. https:\/\/doi.org\/10.1016\/j.mayocp.2024.07.008","DOI":"10.1016\/j.mayocp.2024.07.008"},{"key":"882_CR3","doi-asserted-by":"publisher","unstructured":"Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366. https:\/\/doi.org\/10.1136\/bmj.l4363.","DOI":"10.1136\/bmj.l4363"},{"key":"882_CR4","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","volume":"124","author":"N Van Es","year":"2014","unstructured":"Van Es N, Coppens M, Schulman S, Middeldorp S, B\u00fcller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: Evidence from phase 3 trials. Blood. 2014;124:1968\u201375. https:\/\/doi.org\/10.1182\/blood-2014-04-571232.","journal-title":"Blood"},{"key":"882_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5837\/bjc.2022.001","volume":"29","author":"K White","year":"2022","unstructured":"White K, Faruqi U, Cohen AAT, White K. New agents for DOAC reversal: a practical management review. Br J Cardiol. 2022;29:26\u201330. https:\/\/doi.org\/10.5837\/bjc.2022.001.","journal-title":"Br J Cardiol"},{"key":"882_CR6","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.jtha.2025.02.022","volume":"23","author":"VR Lanting","year":"2025","unstructured":"Lanting VR, van Bergen K, Bosch FTM, Grosso MA, Segers A, Raskob GE, et al. Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study. J Thromb Haemostasis Author(s). 2025;23:2255\u201361. https:\/\/doi.org\/10.1016\/j.jtha.2025.02.022.","journal-title":"J Thromb Haemostasis Author(s)"},{"key":"882_CR7","first-page":"616","volume":"121","author":"W Ageno","year":"2020","unstructured":"Ageno W, Cristina M, Ander V, Menno C, Gussoni G, Becattini C, et al. Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thromb Haemost. 2020;121:616\u201324.","journal-title":"Thromb Haemost"},{"key":"882_CR8","doi-asserted-by":"publisher","first-page":"e03","DOI":"10.15420\/ecr.2024.17","volume":"20","author":"M Bhandari","year":"2025","unstructured":"Bhandari M, Pradhan A, Vishwakarma P, Renzo L, Di, Iellamo F, Ali W, et al. Direct Oral Anticoagulant Use in Older Adults with Atrial Fibrillation: Challenges and Solutions. Eur Cardiol Rev. 2025;20:e03. https:\/\/doi.org\/10.15420\/ecr.2024.17.","journal-title":"Eur Cardiol Rev"},{"key":"882_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.thromres.2017.03.022","volume":"153","author":"P Prandoni","year":"2017","unstructured":"Prandoni P, Ageno W, Mumoli N, Zanatta N, Imberti D, Vison\u00e0 A, et al. Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thromb Res Elsevier Ltd. 2017;153:97\u2013100. https:\/\/doi.org\/10.1016\/j.thromres.2017.03.022.","journal-title":"Thromb Res Elsevier Ltd"},{"key":"882_CR10","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jvsv.2023.03.017","volume":"11","author":"A Javed","year":"2023","unstructured":"Javed A, Machin M, Gwozdz AM, Turner B, Onida S, Shalhoub J, et al. Meta-analysis of lytic catheter-based intervention for acute proximal deep vein thrombosis in the reduction of post-thrombotic syndrome. J Vasc Surg Venous Lymphat Disord Elsevier. 2023;11:866\u2013e8751. https:\/\/doi.org\/10.1016\/j.jvsv.2023.03.017.","journal-title":"J Vasc Surg Venous Lymphat Disord Elsevier"},{"key":"882_CR11","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/clc.23196","volume":"42","author":"V Aursulesei","year":"2019","unstructured":"Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019;42:774\u201382. https:\/\/doi.org\/10.1002\/clc.23196.","journal-title":"Clin Cardiol"},{"key":"882_CR12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Nisio M, Di, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer. Blood Adv. 2021;5:927\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2020003442.","journal-title":"Blood Adv"},{"key":"882_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AYY Lee","year":"2003","unstructured":"Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146\u201353. https:\/\/doi.org\/10.1056\/NEJMoa025313.","journal-title":"N Engl J Med"},{"key":"882_CR14","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.jacc.2020.07.070","volume":"76","author":"E Renner","year":"2020","unstructured":"Renner E, Barnes GD. Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar. J Am Coll Cardiol. 2020;76:2142\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2020.07.070.","journal-title":"J Am Coll Cardiol"},{"key":"882_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.7759\/cureus.85653","volume":"17","author":"D Viswanathan","year":"2025","unstructured":"Viswanathan D, Sivanandam A, De Silva P. Assessment of Time in Therapeutic Range (TTR) in a Primary Care Warfarin Clinic. Cureus. 2025;17:4\u201311. https:\/\/doi.org\/10.7759\/cureus.85653.","journal-title":"Cureus"},{"key":"882_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","volume":"77","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;77:450\u2013500. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.035.","journal-title":"J Am Coll Cardiol"},{"key":"882_CR17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1300615.","journal-title":"N Engl J Med"},{"key":"882_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/jth.15158","volume":"19","author":"V Pengo","year":"2021","unstructured":"Pengo V, Hoxha A, Andreoli L, Tincani A, Silvestri E, Prisco D, et al. Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. J Thromb Haemostasis Elsevier Masson SAS. 2021;19:531\u20135. https:\/\/doi.org\/10.1111\/jth.15158.","journal-title":"J Thromb Haemostasis Elsevier Masson SAS"},{"key":"882_CR19","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/nejmoa1306638","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","unstructured":"The Hokusai-VTE Investigators. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med. 2013;369:1406\u201315. https:\/\/doi.org\/10.1056\/nejmoa1306638.","journal-title":"N Engl J Med"},{"key":"882_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507.","journal-title":"N Engl J Med"},{"key":"882_CR21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR B\u00fcller","year":"2012","unstructured":"B\u00fcller HR, Prins MH, Lensing AWA, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1113572.","journal-title":"N Engl J Med"},{"key":"882_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MBC.0000000000000800","volume":"30","author":"AT Cohen","year":"2019","unstructured":"Cohen AT, Bauersachs R. Rivaroxaban and the Einstein clinical trial programme. Blood Coag Fibrinol. 2019;30:85\u201395. https:\/\/doi.org\/10.1097\/MBC.0000000000000800.","journal-title":"Blood Coag Fibrinol"},{"key":"882_CR23","doi-asserted-by":"publisher","unstructured":"Zhao Y, Guo M, Li D, Xu W, Pan C, He C, et al. Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients: an updated literature review. Clin Appl Thromb Hemost. 2023;29. https:\/\/doi.org\/10.1177\/10760296231153638.","DOI":"10.1177\/10760296231153638"},{"key":"882_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/jth.13912","volume":"16","author":"J Douxfils","year":"2018","unstructured":"Douxfils J, Ageno W, Samama CM, Lessire S, ten Cate H, Verhamme P, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16:209\u201319. https:\/\/doi.org\/10.1111\/jth.13912.","journal-title":"J Thromb Haemost"},{"key":"882_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/acem.12711","volume":"22","author":"DM Beam","year":"2015","unstructured":"Beam DM, Kahler ZP, Kline JA. Immediate Discharge and Home Treatment with Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis. Acad Emerg Med. 2015;22:789\u201395. https:\/\/doi.org\/10.1111\/acem.12711.","journal-title":"Acad Emerg Med"},{"key":"882_CR26","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1111\/bcp.13985","volume":"85","author":"SK Afzal","year":"2019","unstructured":"Afzal SK, Hasan SS, Babar ZU. A systematic review of patient-reported outcomes associated with the use of direct-acting oral anticoagulants. Br J Clin Pharmacol. 2019;85:2652\u201367. https:\/\/doi.org\/10.1111\/bcp.13985.","journal-title":"Br J Clin Pharmacol"},{"key":"882_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11239-021-02437-z","volume":"52","author":"MC Fang","year":"2021","unstructured":"Fang MC, Go AS, Barnes GD, Hernandez I, Chang Y, Haas S, et al. Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism. J Thromb Thrombolysis. 2021;52:34\u201343. https:\/\/doi.org\/10.1007\/s11239-021-02437-z.","journal-title":"J Thromb Thrombolysis"},{"key":"882_CR28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1207541.","journal-title":"N Engl J Med"},{"key":"882_CR29","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/nejmoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017;376:1211\u201322. https:\/\/doi.org\/10.1056\/nejmoa1700518.","journal-title":"N Engl J Med"},{"key":"882_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","volume":"405","author":"F Couturaud","year":"2025","unstructured":"Couturaud F, Schmidt J, Sanchez O, Ballerie A, Sevestre MA, Meneveau N, et al. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet. 2025;405:725\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(24)02842-3.","journal-title":"Lancet"},{"key":"882_CR31","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/nejmoa1302097","volume":"370","author":"G Meyer","year":"2014","unstructured":"Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. N Engl J Med. 2014;370:1402\u201311. https:\/\/doi.org\/10.1056\/nejmoa1302097.","journal-title":"N Engl J Med"},{"key":"882_CR32","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/nejmoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319\u201330. https:\/\/doi.org\/10.1056\/nejmoa1709118.","journal-title":"N Engl J Med"},{"key":"882_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtha.2023.09.020","volume":"22","author":"A Jones","year":"2024","unstructured":"Jones A, Swan D, Lisman T, Barnes GD, Thachil J. Anticoagulation in chronic kidney disease: current status and future perspectives. J Thromb Haemostasis Int Soc Thromb Haemostasis. 2024;22:323\u201336. https:\/\/doi.org\/10.1016\/j.jtha.2023.09.020.","journal-title":"J Thromb Haemostasis Int Soc Thromb Haemostasis"},{"key":"882_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00228-024-03648-y","volume":"80","author":"MME Diesveld","year":"2024","unstructured":"Diesveld MME, Pijnenburg DWMJ, Weersink RA, Barzel I, Drenth JPH, Lisman T, et al. Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data. Eur J Clin Pharmacol Springer Berlin Heidelberg. 2024;80:797\u2013812. https:\/\/doi.org\/10.1007\/s00228-024-03648-y.","journal-title":"Eur J Clin Pharmacol Springer Berlin Heidelberg"},{"key":"882_CR35","first-page":"60","volume":"100","author":"Y Dhaha","year":"2022","unstructured":"Dhaha Y, El Borgi W, Elmahmoudi H, Achour M, Salem SF, Lakhal F, Ben, et al. Factor XI deficiency: About 20 cases and literature review D\u00e9ficit en facteur XI: A propos de 20 cas et revue de la litt\u00e9rature. Tunis Med. 2022;100:60\u20135.","journal-title":"Tunis Med"},{"key":"882_CR36","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s12185-022-03390-0","volume":"116","author":"SC Chou","year":"2022","unstructured":"Chou SC, Lin CY, Lin HY, Pai CH, Yu CY, Kuo SF, et al. Characterization of congenital factor XII deficiency in Taiwanese patients: identification of one novel and one common mutation. Int J Hematol Springer Nat Singap. 2022;116:528\u201333. https:\/\/doi.org\/10.1007\/s12185-022-03390-0.","journal-title":"Int J Hematol Springer Nat Singap"},{"key":"882_CR37","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, Rennert G, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129:1210\u20135. https:\/\/doi.org\/10.1182\/blood-2016-09-742262.","journal-title":"Blood"},{"key":"882_CR38","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1111\/jth.15037","volume":"18","author":"SP Grover","year":"2020","unstructured":"Grover SP, Olson TM, Cooley BC, Mackman N. Model-dependent contributions of FXII and FXI to venous thrombosis in mice. J Thromb Haemost. 2020;18:2899\u2013909. https:\/\/doi.org\/10.1111\/jth.15037.","journal-title":"J Thromb Haemost"},{"key":"882_CR39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1056\/nejme2412901","volume":"392","author":"DJ Angiolillo","year":"2025","unstructured":"Angiolillo DJ, Capodanno D. Uncoupling Thrombosis and Hemostasis by Inhibiting Factor XI. N Engl J Med. 2025;392:398\u2013400. https:\/\/doi.org\/10.1056\/nejme2412901.","journal-title":"N Engl J Med"},{"key":"882_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s43044-024-00570-7","volume-title":"The third-generation anticoagulants: factors XI, XII, and XIII inhibitors. Egyptian Heart Journal","author":"S Prajapathi","year":"2024","unstructured":"Prajapathi S, Pradhan A, Mohta A, Sethi R. The third-generation anticoagulants: factors XI, XII, and XIII inhibitors. Egyptian Heart Journal. Berlin Heidelberg: Springer; 2024. p. 76. https:\/\/doi.org\/10.1186\/s43044-024-00570-7."},{"key":"882_CR41","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.jacc.2019.08.1028","volume":"74","author":"V Pireaux","year":"2019","unstructured":"Pireaux V, Tassignon J, Demoulin S, Derochette S, Borenstein N, Ente A, et al. Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass. J Am Coll Cardiol. 2019;74:2178\u201389. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.1028.","journal-title":"J Am Coll Cardiol"},{"key":"882_CR42","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021011725","volume":"138","author":"CU Lorentz","year":"2021","unstructured":"Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138:2173\u201384. https:\/\/doi.org\/10.1182\/blood.2021011725.","journal-title":"Blood"},{"key":"882_CR43","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/jth.15439","volume":"19","author":"D Thomas","year":"2021","unstructured":"Thomas D, Kanefendt F, Schwers S, Unger S, Yassen A, Boxnick S. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J Thromb Haemost. 2021;19:2407\u201316. https:\/\/doi.org\/10.1111\/jth.15439.","journal-title":"J Thromb Haemost"},{"key":"882_CR44","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","volume":"147","author":"A Greco","year":"2023","unstructured":"Greco A, Laudani C, Spagnolo M, Agnello F, Faro DC, Finocchiaro S, et al. Pharmacology and Clinical Development of Factor XI Inhibitors. Circulation. 2023;147:897\u2013913. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062353.","journal-title":"Circulation"},{"key":"882_CR45","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/nejmoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, B\u00fcller HR, et al. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021;385:609\u201317. https:\/\/doi.org\/10.1056\/nejmoa2105872.","journal-title":"N Engl J Med"},{"key":"882_CR46","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","volume":"431","author":"M Schaefer","year":"2019","unstructured":"Schaefer M, Buchmueller A, Dittmer F, Stra\u00dfburger J, Wilmen A. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol. 2019;431:4817\u201333. https:\/\/doi.org\/10.1016\/j.jmb.2019.09.008.","journal-title":"J Mol Biol"},{"key":"882_CR47","doi-asserted-by":"publisher","unstructured":"Satpathy C, Mishra TK, Jha AK. Factor XI and XII inhibitors\u2013Dawn of a new era. Indian Heart J. Elsevier, a division of RELX India, Pvt. Ltd; 2025;77:122\u20139. https:\/\/doi.org\/10.1016\/j.ihj.2025.02.007","DOI":"10.1016\/j.ihj.2025.02.007"},{"key":"882_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cts.13784","volume":"17","author":"T Liu","year":"2024","unstructured":"Liu T, Hashizume K, Krieg E, Chen H, Mukaida Y, Thelen K, et al. Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. Clin Transl Sci. 2024;17:1\u201313. https:\/\/doi.org\/10.1111\/cts.13784.","journal-title":"Clin Transl Sci"},{"key":"882_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","volume":"7","author":"M Walsh","year":"2022","unstructured":"Walsh M, Bethune C, Smyth A, Tyrwhitt J, Jung SW, Yu RZ, et al. Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD. Kidney Int Rep. 2022;7:200\u20139. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.011.","journal-title":"Kidney Int Rep"},{"key":"882_CR50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1161\/ATVBAHA.123.319692","volume":"44","author":"MA Pfeffer","year":"2024","unstructured":"Pfeffer MA, Kohs TCL, Vu HH, Jordan KR, Wang JSH, Lorentz CU, et al. Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients with Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial. Arterioscler Thromb Vasc Biol. 2024;44:290\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.123.319692.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"882_CR51","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/nejmoa1405760","volume":"372","author":"HR B\u00fcller","year":"2015","unstructured":"B\u00fcller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al. Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. N Engl J Med. 2015;372:232\u201340. https:\/\/doi.org\/10.1056\/nejmoa1405760.","journal-title":"N Engl J Med"},{"key":"882_CR52","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/nejmoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021;385:2161\u201372. https:\/\/doi.org\/10.1056\/nejmoa2113194.","journal-title":"N Engl J Med"},{"key":"882_CR53","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020;323:130\u20139. https:\/\/doi.org\/10.1001\/jama.2019.20687.","journal-title":"JAMA"},{"key":"882_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcvm.2022.903029","volume":"9","author":"S Nopp","year":"2022","unstructured":"Nopp S, Kraemmer D, Ay C. Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence. Front Cardiovasc Med. 2022;9:1\u201310. https:\/\/doi.org\/10.3389\/fcvm.2022.903029.","journal-title":"Front Cardiovasc Med"},{"key":"882_CR55","doi-asserted-by":"publisher","unstructured":"Fioretti AM, Leopizzi T, Forgia D, De La R, Oreste D, Inchingolo R, et al. Abelacimab in cancer-associated thrombosis: the right drug at the right time for the right purpose. Compr Rev Rev Cardiovasc Med. 2023;24. https:\/\/doi.org\/10.31083\/j.rcm2410295.","DOI":"10.31083\/j.rcm2410295"},{"key":"882_CR56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/nejmoa2407105","volume":"392","author":"JP Piccini","year":"2025","unstructured":"Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2025;392:23\u201332. https:\/\/doi.org\/10.1056\/nejmoa2407105.","journal-title":"N Engl J Med"},{"key":"882_CR57","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022;399:1383\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00456-1.","journal-title":"Lancet"},{"key":"882_CR58","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","volume":"106","author":"WC Winkelmayer","year":"2024","unstructured":"Winkelmayer WC, Lensing AWA, Thadhani RI, Mahaffey KW, Walsh M, Pap \u00c1F, et al. A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney Int. 2024;106:145\u201353. https:\/\/doi.org\/10.1016\/j.kint.2024.02.024.","journal-title":"Kidney Int"},{"key":"882_CR59","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","volume":"30","author":"JI Weitz","year":"2024","unstructured":"Weitz JI, Tank\u00f3 LB, Floege J, Fox KAA, Bhatt DL, Thadhani R, et al. Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial. Nat Med United States. 2024;30:435\u201342. https:\/\/doi.org\/10.1038\/s41591-023-02794-7.","journal-title":"Nat Med United States"},{"key":"882_CR60","doi-asserted-by":"publisher","DOI":"10.5837\/bjc.2024.018","author":"MA Sammut","year":"2024","unstructured":"Sammut MA, Elamin N, Storey RF, Sammut MA. Factor XI and XIa inhibition: a new approach to anticoagulant therapy. Br J Cardiol. 2024. https:\/\/doi.org\/10.5837\/bjc.2024.018.","journal-title":"Br J Cardiol"},{"key":"882_CR61","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Bueno H, Gali\u00e9 N, Gibbs JSR, Ageno W, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J. 2020;41:543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405.","journal-title":"Eur Heart J"},{"key":"882_CR62","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1161\/STR.0000000000000152","volume":"48","author":"S Yaghi","year":"2017","unstructured":"Yaghi S, Willey JZ, Cucchiara B, Goldstein JN, Gonzales NR, Khatri P, et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2017;48:e343\u201361. https:\/\/doi.org\/10.1161\/STR.0000000000000152.","journal-title":"Stroke"},{"key":"882_CR63","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1182\/bloodadvances.2020001513","volume":"4","author":"A Izcovich","year":"2020","unstructured":"Izcovich A, Criniti JM, Popoff F, Lu L, Wu J, Ageno W, et al. Thrombolytics for venous thromboembolic events: A systematic review with meta-analysis. Blood Adv. 2020;4:1539\u201353. https:\/\/doi.org\/10.1182\/bloodadvances.2020001513.","journal-title":"Blood Adv"},{"key":"882_CR64","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/nejmoa1615066","volume":"377","author":"S Vedantham","year":"2017","unstructured":"Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. N Engl J Med. 2017;377:2240\u201352. https:\/\/doi.org\/10.1056\/nejmoa1615066.","journal-title":"N Engl J Med"},{"key":"882_CR65","doi-asserted-by":"publisher","unstructured":"Broderick C, Watson L, Armon MP. Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database Syst Reviews. 2021;2021. https:\/\/doi.org\/10.1002\/14651858.CD002783.pub5.","DOI":"10.1002\/14651858.CD002783.pub5"},{"key":"882_CR66","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/jth.15701","volume":"20","author":"T Frischmuth","year":"2022","unstructured":"Frischmuth T, Hindberg K, Aukrust P, Ueland T, Br\u00e6kkan SK, Hansen JB, et al. Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism. J Thromb Haemostasis Elsevier Masson SAS. 2022;20:1618\u201326. https:\/\/doi.org\/10.1111\/jth.15701.","journal-title":"J Thromb Haemostasis Elsevier Masson SAS"},{"key":"882_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-80010-z","volume":"11","author":"Y Zuo","year":"2021","unstructured":"Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep Nat Publishing Group UK. 2021;11:1\u20139. https:\/\/doi.org\/10.1038\/s41598-020-80010-z.","journal-title":"Sci Rep Nat Publishing Group UK"},{"key":"882_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13256-021-02813-6","volume":"15","author":"BAB Mohammed","year":"2021","unstructured":"Mohammed BAB. Alpha 2-antiplasmin deficiency in a Sudanese child: a case report. J Med Case Rep. 2021;15:1\u20135. https:\/\/doi.org\/10.1186\/s13256-021-02813-6.","journal-title":"J Med Case Rep"},{"key":"882_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22052721","volume":"22","author":"M Sillen","year":"2021","unstructured":"Sillen M, Declerck PJ. A narrative review on plasminogen activator inhibitor-1 and its (Patho)physiological role: To target or not to target? Int J Mol Sci. 2021;22:1\u201316. https:\/\/doi.org\/10.3390\/ijms22052721.","journal-title":"Int J Mol Sci"},{"key":"882_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020883","author":"K Claesen","year":"2021","unstructured":"Claesen K, Mertens JC, Leenaerts D, Hendriks D. Carboxypeptidase U (CPU, TAFIa, CPB2) in thromboembolic disease: What do we know three decades after its discovery? Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22020883.","journal-title":"Int J Mol Sci"},{"key":"882_CR71","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/jth.12657","volume":"12","author":"SA Siefert","year":"2014","unstructured":"Siefert SA, Chabasse C, Mukhopadhyay S, Hoofnagle MH, Strickland DK, Sarkar R, et al. Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice. J Thromb Haemost. 2014;12:1706\u201316. https:\/\/doi.org\/10.1111\/jth.12657.","journal-title":"J Thromb Haemost"},{"key":"882_CR72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jtha.2023.09.016","volume":"22","author":"JE Chessum","year":"2024","unstructured":"Chessum JE, Shaya SA, Rajab D, Aftabjahani A, Zhou J, Weitz JI, et al. Thrombin-activatable fibrinolysis inhibitor and sex modulate thrombus stability and pulmonary embolism burden in a murine model. J Thromb Haemostasis Int Soc Thromb Haemostasis. 2024;22:263\u201370. https:\/\/doi.org\/10.1016\/j.jtha.2023.09.016.","journal-title":"J Thromb Haemostasis Int Soc Thromb Haemostasis"},{"key":"882_CR73","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1161\/CIRCULATIONAHA.124.069728","volume":"150","author":"S Singh","year":"2024","unstructured":"Singh S, Kumar P, Padwad YS, Jaffer FA, Reed GL. Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach. Circulation. 2024;150:884\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069728.","journal-title":"Circulation"},{"key":"882_CR74","doi-asserted-by":"publisher","unstructured":"Verstraete A, Van Thillo Q, Vanassche T, Verhamme P. New horizons in the pharmacological management of venous thromboembolism. Hemasphere. 2025;9. https:\/\/doi.org\/10.1002\/hem3.70143.","DOI":"10.1002\/hem3.70143"},{"key":"882_CR75","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/jth.13658","volume":"15","author":"J Zhou","year":"2017","unstructured":"Zhou J, Kochan J, Yin O, Warren V, Zamora C, Atiee G, et al. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects. J Thromb Haemostasis Elsevier Masson SAS. 2017;15:961\u201371. https:\/\/doi.org\/10.1111\/jth.13658.","journal-title":"J Thromb Haemostasis Elsevier Masson SAS"},{"key":"882_CR76","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.jtha.2023.04.037","volume":"21","author":"T Vanassche","year":"2023","unstructured":"Vanassche T, Rosovsky RP, Moustafa F, B\u00fcller HR, Segers A, Patel I, et al. Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study. J Thromb Haemost. 2023;21:2929\u201340. https:\/\/doi.org\/10.1016\/j.jtha.2023.04.037.","journal-title":"J Thromb Haemost"},{"key":"882_CR77","doi-asserted-by":"publisher","unstructured":"Dop F, Latreille M, Guicherd L, Mertens J, Claesen K, Hendriks D, et al. Favourable safety profile of S62798, a potent TAFIa (activated thrombin-activatable fibrinolysis inhibitor) inhibitor, in first-in-man study in healthy subjects. Eur Heart J. 2020;41. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.2268.","DOI":"10.1093\/ehjci\/ehaa946.2268"},{"key":"882_CR78","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1111\/j.1538-7836.2009.03596.x","volume":"7","author":"JL Willemse","year":"2009","unstructured":"Willemse JL, Heylen E, Nesheim ME, Hendriks DF. Carboxypeptidase U (TAFIa): A new drug target for fibrinolytic therapy? J Thromb Haemostasis Elsevier Masson SAS. 2009;7:1962\u201371. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03596.x.","journal-title":"J Thromb Haemostasis Elsevier Masson SAS"},{"key":"882_CR79","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-3-030-95997-5_2","volume":"44","author":"M Palazzini","year":"2022","unstructured":"Palazzini M, Saia F, Guarino D, Taglieri N, Manes A, Gali\u00e8 N, et al. Diagnosis of Chronic Thromboembolic Pulmonary Hypertension. Balloon Pulmonary Angioplasty in Patients with CTEPH. Elsevier Inc. 2022;44:13\u201322. https:\/\/doi.org\/10.1007\/978-3-030-95997-5_2.","journal-title":"Elsevier Inc"},{"key":"882_CR80","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1086\/686011","volume":"6","author":"DT Matthews","year":"2016","unstructured":"Matthews DT, Hemnes AR. Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. Pulm Circ. 2016;6:145\u201354. https:\/\/doi.org\/10.1086\/686011.","journal-title":"Pulm Circ"},{"key":"882_CR81","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1182\/blood.2023022522","volume":"144","author":"J Rayes","year":"2024","unstructured":"Rayes J, Brill A. Hot under the clot: venous thrombogenesis is an inflammatory process. Blood Am Soc Hematol. 2024;144:477\u201389. https:\/\/doi.org\/10.1182\/blood.2023022522.","journal-title":"Blood Am Soc Hematol"},{"key":"882_CR82","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1538-7836.2011.04544.x","volume":"10","author":"A Brill","year":"2012","unstructured":"Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, de Meyer SF, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10:136\u201344. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04544.x.","journal-title":"J Thromb Haemost"},{"key":"882_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2024.1401399","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang J, Huang S, Zhu Z, Gatt A, Liu J. E-selectin in vascular pathophysiology. Front Immunol. 2024;15:1\u20139. https:\/\/doi.org\/10.3389\/fimmu.2024.1401399.","journal-title":"Front Immunol"},{"key":"882_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01933-x","volume":"9","author":"H Wang","year":"2024","unstructured":"Wang H, Kim SJ, Lei Y, Wang S, Wang H, Huang H, et al. Neutrophil extracellular traps in homeostasis and disease. Signal Transduct Target Ther Springer US. 2024;9:1\u201340. https:\/\/doi.org\/10.1038\/s41392-024-01933-x.","journal-title":"Signal Transduct Target Ther Springer US"},{"key":"882_CR85","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jvs.2006.05.021","volume":"44","author":"DD Myers","year":"2006","unstructured":"Myers DD, Henke PK, Bedard PW, Wrobleski SK, Kaila N, Shaw G, et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg. 2006;44:625\u201332. https:\/\/doi.org\/10.1016\/j.jvs.2006.05.021.","journal-title":"J Vasc Surg"},{"key":"882_CR86","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1067\/msy.2003.249","volume":"134","author":"P Thanaporn","year":"2003","unstructured":"Thanaporn P, Myers DD, Wrobleski SK, Hawley AE, Farris DM, Wakefield TW, et al. P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model. Surgery. 2003;134:365\u201371. https:\/\/doi.org\/10.1067\/msy.2003.249.","journal-title":"Surgery"},{"key":"882_CR87","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1124\/jpet.107.128124","volume":"324","author":"PW Bedard","year":"2008","unstructured":"Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther Neth. 2008;324:497\u2013506. https:\/\/doi.org\/10.1124\/jpet.107.128124.","journal-title":"J Pharmacol Exp Ther Neth"},{"key":"882_CR88","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/jth.15689","volume":"20","author":"M Purdy","year":"2022","unstructured":"Purdy M, Obi A, Myers D, Wakefield T. P- and E- selectin in venous thrombosis and non-venous pathologies. J Thromb Haemost Engl. 2022;20:1056\u201366. https:\/\/doi.org\/10.1111\/jth.15689.","journal-title":"J Thromb Haemost Engl"},{"key":"882_CR89","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jvsv.2020.12.086","volume":"10","author":"DD Myers","year":"2022","unstructured":"Myers DD Jr., Ning J, Lester P, Adili R, Hawley A, Durham L, et al. E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis. J Vasc Surg Venous Lymphat Disord Elsevier. 2022;10:211\u201320. https:\/\/doi.org\/10.1016\/j.jvsv.2020.12.086.","journal-title":"J Vasc Surg Venous Lymphat Disord Elsevier"},{"key":"882_CR90","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/ATVBAHA.114.304457","volume":"35","author":"JA Diaz","year":"2015","unstructured":"Diaz JA, Wrobleski SK, Alvarado CM, Hawley AE, Doornbos NK, Lester PA, et al. P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor. Arterioscler Thromb Vasc Biol United States. 2015;35:829\u201337. https:\/\/doi.org\/10.1161\/ATVBAHA.114.304457.","journal-title":"Arterioscler Thromb Vasc Biol United States"},{"key":"882_CR91","doi-asserted-by":"publisher","unstructured":"Muz B, Azab F, Puente P, De, Rollins S, Alvarez R, Kawar Z, et al. Inhibition of P-selectin and PSGL-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to bortezomib. Hindawi Publishing Corporation. 2015;2015. https:\/\/doi.org\/10.1155\/2015\/417586","DOI":"10.1155\/2015\/417586"},{"key":"882_CR92","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1182\/blood.2021010721","volume":"139","author":"DJ Deangelo","year":"2022","unstructured":"Deangelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P, et al. Phase 1 \/ 2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022;139:1135\u201346.","journal-title":"Blood"},{"key":"882_CR93","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","volume":"376","author":"JK Madden","year":"2017","unstructured":"Madden JK, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017;376:429\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1611770.","journal-title":"N Engl J Med"},{"key":"882_CR94","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","volume":"112","author":"C Ay","year":"2008","unstructured":"Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood United States. 2008;112:2703\u20138. https:\/\/doi.org\/10.1182\/blood-2008-02-142422.","journal-title":"Blood United States"},{"key":"882_CR95","doi-asserted-by":"publisher","first-page":"e70368","DOI":"10.1002\/ctm2.70368","volume":"15","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang K, Li J, Wang C, Li P, Du L. Neutrophil extracellular traps in cancer: From mechanisms to treatments. Clin Transl Med United States. 2025;15:e70368. https:\/\/doi.org\/10.1002\/ctm2.70368.","journal-title":"Clin Transl Med United States"},{"key":"882_CR96","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","volume":"397","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, de Barros E, Silva PGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet Engl. 2021;397:2253\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(21)01203-4.","journal-title":"Lancet Engl"},{"key":"882_CR97","doi-asserted-by":"publisher","first-page":"109135","DOI":"10.1016\/j.thromres.2024.109135","volume":"243","author":"LM Almskog","year":"2024","unstructured":"Almskog LM, Sj\u00f6str\u00f6m A, Sund\u00e9n-Cullberg J, Taxiarchis A, \u00c5gren A, Freyland S, et al. Tocilizumab reduces hypercoagulation in COVID-19 - Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial. Thromb Res United States. 2024;243:109135. https:\/\/doi.org\/10.1016\/j.thromres.2024.109135.","journal-title":"Thromb Res United States"},{"key":"882_CR98","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","volume":"1","author":"MH Prins","year":"2014","unstructured":"Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol Engl. 2014;1:e37\u201346. https:\/\/doi.org\/10.1016\/S2352-3026(14)70018-3.","journal-title":"Lancet Haematol Engl"},{"key":"882_CR99","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost Engl. 2020;18:411\u201321. https:\/\/doi.org\/10.1111\/jth.14662.","journal-title":"J Thromb Haemost Engl"},{"key":"882_CR100","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol United States. 2018;36:2017\u201323. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034.","journal-title":"J Clin Oncol United States"},{"key":"882_CR101","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12959-022-00399-7","volume":"20","author":"T Rungjirajittranon","year":"2022","unstructured":"Rungjirajittranon T, Owattanapanich W, Chinthammitr Y, Ruchutrakool T, Suwanawiboon B. Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis. Thromb J Engl. 2022;20:41. https:\/\/doi.org\/10.1186\/s12959-022-00399-7.","journal-title":"Thromb J Engl"},{"key":"882_CR102","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3324\/haematol.2021.279072","volume":"107","author":"C Becattini","year":"2022","unstructured":"Becattini C, Bauersachs R, Maraziti G, Bertoletti L, Cohen A, Connors JM, et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematol Italy. 2022;107:1567\u201376. https:\/\/doi.org\/10.3324\/haematol.2021.279072.","journal-title":"Haematol Italy"},{"key":"882_CR103","doi-asserted-by":"publisher","unstructured":"Frere C, Farge D, Schrag D, Prata PH, Connors JM. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol England. 2022:69. https:\/\/doi.org\/10.1186\/s13045-022-01289-1","DOI":"10.1186\/s13045-022-01289-1"},{"key":"882_CR104","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/oncolo\/oyad116","volume":"28","author":"T-F Wang","year":"2023","unstructured":"Wang T-F, Khorana AA, Agnelli G, Bloomfield D, Bonaca MP, B\u00fcller HR, et al. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. Oncologist Engl. 2023;28:555\u201364. https:\/\/doi.org\/10.1093\/oncolo\/oyad116.","journal-title":"Oncologist Engl"},{"key":"882_CR105","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1016\/j.jtha.2023.06.009","volume":"21","author":"FTM Bosch","year":"2023","unstructured":"Bosch FTM, Campello E, Mulder FI, Ilich A, Henderson MW, Prokopenko Y, et al. Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: a prospective cohort study. J Thromb Haemost Engl. 2023;21:2863\u201372. https:\/\/doi.org\/10.1016\/j.jtha.2023.06.009.","journal-title":"J Thromb Haemost Engl"},{"key":"882_CR106","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1111\/jgs.70127","volume":"73","author":"LC Klickstein","year":"2025","unstructured":"Klickstein LC, Niznik J, Branham V, George H, Meyer ML, Busby-Whitehead J, et al. Appropriateness of Antiplatelets and Anticoagulants Among Older Adults Experiencing Falls. J Am Geriatr Soc United States. 2025;73:3670\u20138. https:\/\/doi.org\/10.1111\/jgs.70127.","journal-title":"J Am Geriatr Soc United States"},{"key":"882_CR107","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jacc.2025.05.060","volume":"86","author":"AM Nicolau","year":"2025","unstructured":"Nicolau AM, Giugliano RP, Zimerman A, Afilalo J, Gencer B, Steffel J, et al. Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy. J Am Coll Cardiol United States. 2025;86:426\u201339. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.060.","journal-title":"J Am Coll Cardiol United States"},{"key":"882_CR108","doi-asserted-by":"publisher","unstructured":"Thomas A, Fang MC, Kogan S, Hubbard CC, Friedman PN, Gong L, et al. Apixaban concentrations in routine clinical care of older adults with nonvalvular atrial fibrillation. JACC Adv United States. 2022;1. https:\/\/doi.org\/10.1016\/j.jacadv.2022.100039.","DOI":"10.1016\/j.jacadv.2022.100039"},{"key":"882_CR109","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1111\/jgs.15982","volume":"67","author":"S Sukumar","year":"2019","unstructured":"Sukumar S, Gulilat M, Linton B, Gryn SE, Dresser GK, Alfonsi JE, et al. Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. J Am Geriatr Soc United States. 2019;67:1902\u20136. https:\/\/doi.org\/10.1111\/jgs.15982.","journal-title":"J Am Geriatr Soc United States"},{"key":"882_CR110","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1161\/STROKEAHA.118.021387","volume":"49","author":"HT Yu","year":"2018","unstructured":"Yu HT, Yang P-S, Kim T-H, Jang E, Kim D, Uhm J-S, et al. Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation. Stroke United States. 2018;49:2421\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.118.021387.","journal-title":"Stroke United States"},{"key":"882_CR111","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing G-J, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest United States. 2021;160:e545\u2013608. https:\/\/doi.org\/10.1016\/j.chest.2021.07.055.","journal-title":"Chest United States"},{"key":"882_CR112","doi-asserted-by":"publisher","unstructured":"Go Y-H, Lee S-R, Choi E-K, Ahn H-J, Han K-D, Oh S, et al. Direct oral anticoagulants in very elderly and high-bleeding-risk patients with atrial fibrillation often excluded from oral anticoagulation therapy: a nationwide population-based cohort study. Europace Engl. 2025;27. https:\/\/doi.org\/10.1093\/europace\/euaf230.","DOI":"10.1093\/europace\/euaf230"},{"key":"882_CR113","doi-asserted-by":"publisher","first-page":"e031506","DOI":"10.1161\/JAHA.123.031506","volume":"13","author":"M Akao","year":"2024","unstructured":"Akao M, Yamashita T, Fukuzawa M, Hayashi T, Okumura K. Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial. J Am Heart Assoc Engl. 2024;13:e031506. https:\/\/doi.org\/10.1161\/JAHA.123.031506.","journal-title":"J Am Heart Assoc Engl"},{"key":"882_CR114","doi-asserted-by":"publisher","first-page":"151484","DOI":"10.1016\/j.semnephrol.2023.151484","volume":"43","author":"M Ades","year":"2023","unstructured":"Ades M, Simard C, Vanassche T, Verhamme P, Eikelboom J, Mavrakanas TA, Factor XI, Inhibitors. Potential Role in End-Stage Kidney Disease. Semin Nephrol United States. 2023;43:151484. https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151484.","journal-title":"Semin Nephrol United States"},{"key":"882_CR115","doi-asserted-by":"publisher","first-page":"102584","DOI":"10.1016\/j.rpth.2024.102584","volume":"8","author":"D Tham","year":"2024","unstructured":"Tham D, Zhao L, Yu W, Kherani J, Kou R, Li A, et al. Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis. Res Pract Thromb Haemost United States. 2024;8:102584. https:\/\/doi.org\/10.1016\/j.rpth.2024.102584.","journal-title":"Res Pract Thromb Haemost United States"},{"key":"882_CR116","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.thromres.2024.109120","volume":"242","author":"C Jessica","year":"2024","unstructured":"Jessica C, Kevin V, Marie VA, Marica B, Maria CM, Emanuel F, et al. A comparative study on the haemostatic changes in kidney failure patients: Pre- and post- haemodialysis and haemodiafiltration. Thromb Res United States. 2024;242:109\u201320. https:\/\/doi.org\/10.1016\/j.thromres.2024.109120.","journal-title":"Thromb Res United States"},{"key":"882_CR117","doi-asserted-by":"publisher","first-page":"sfae270","DOI":"10.1093\/ckj\/sfae270","volume":"17","author":"GH Heine","year":"2024","unstructured":"Heine GH, Schneppe C, Bauersachs R, Eitel I, Neuen BL, Ruff CT, et al. Ten tips to manage oral anticoagulation in hemodialysis patients with atrial fibrillation. Clin Kidney J Engl. 2024;17:sfae270. https:\/\/doi.org\/10.1093\/ckj\/sfae270.","journal-title":"Clin Kidney J Engl"},{"key":"882_CR118","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","volume":"100","author":"J Eikelboom","year":"2021","unstructured":"Eikelboom J, Floege J, Thadhani R, Weitz JI, Winkelmayer WC. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney Int United States. 2021;100:1199\u2013207. https:\/\/doi.org\/10.1016\/j.kint.2021.08.028.","journal-title":"Kidney Int United States"},{"key":"882_CR119","doi-asserted-by":"publisher","unstructured":"Hylek EM, Anania FA. Oral anticoagulants in liver disease: not child\u2019s play. J Am Coll Cardiol. United States; 2019. pp. 3309\u201311. https:\/\/doi.org\/10.1016\/j.jacc.2019.05.009","DOI":"10.1016\/j.jacc.2019.05.009"},{"key":"882_CR120","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/bjh.19734","volume":"205","author":"LN Roberts","year":"2024","unstructured":"Roberts LN, Thachil J. Prevention and management of venous thrombosis in patients with cirrhosis. Br J Haematol Engl. 2024;205:1717\u20139. https:\/\/doi.org\/10.1111\/bjh.19734.","journal-title":"Br J Haematol Engl"},{"key":"882_CR121","doi-asserted-by":"publisher","unstructured":"Liver EA. for the S of the. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol. Netherlands; 2022;76:1151\u201384. https:\/\/doi.org\/10.1016\/j.jhep.2021.09.003","DOI":"10.1016\/j.jhep.2021.09.003"},{"key":"882_CR122","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1182\/blood-2023-184638","volume":"142","author":"D Tham","year":"2023","unstructured":"Tham D, Bhsc WY, Zhao L, Bhsc RK, Kherani J, Li PY, et al. Safety and Efficacy of Direct Oral Anticoagulants in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis. Blood Am Soc Hematol. 2023;142:5534. https:\/\/doi.org\/10.1182\/blood-2023-184638.","journal-title":"Blood Am Soc Hematol"},{"key":"882_CR123","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4254\/wjh.v15.i6.841","volume":"15","author":"D Juneja","year":"2023","unstructured":"Juneja D, Nasa P, Jain R. Liver injury from direct oral anticoagulants. World J Hepatol United States. 2023;15:841\u20139. https:\/\/doi.org\/10.4254\/wjh.v15.i6.841.","journal-title":"World J Hepatol United States"},{"key":"882_CR124","doi-asserted-by":"publisher","first-page":"e45949","DOI":"10.7759\/cureus.45949","volume":"15","author":"BR Karki","year":"2023","unstructured":"Karki BR, Jasaraj RB, Jha SK, Maisuradze N, Yu Q. An Uncommon Side Effect of Rivaroxaban: A Drug-Induced Liver Injury. Cureus United States. 2023;15:e45949. https:\/\/doi.org\/10.7759\/cureus.45949.","journal-title":"Cureus United States"},{"key":"882_CR125","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.dld.2024.05.020","volume":"56","author":"A Zanetto","year":"2024","unstructured":"Zanetto A, Campello E, Spiezia L, Gavasso S, Bulato C, Burra P, et al. Coagulation factor XI in cirrhosis does not predict thrombo-hemorrhagic complications and hepatic decompensation. Dig Liver Dis Neth. 2024;56:2111\u20137. https:\/\/doi.org\/10.1016\/j.dld.2024.05.020.","journal-title":"Dig Liver Dis Neth"},{"key":"882_CR126","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/ejh.12844","volume":"98","author":"J Hum","year":"2017","unstructured":"Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol Engl. 2017;98:393\u20137. https:\/\/doi.org\/10.1111\/ejh.12844.","journal-title":"Eur J Haematol Engl"},{"key":"882_CR127","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","volume":"79","author":"DE Kaplan","year":"2024","unstructured":"Kaplan DE, Ripoll C, Thiele M, Fortune BE, Simonetto DA, Garcia-Tsao G, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatol United States. 2024;79:1180\u2013211. https:\/\/doi.org\/10.1097\/HEP.0000000000000647.","journal-title":"Hepatol United States"},{"key":"882_CR128","doi-asserted-by":"publisher","first-page":"107602962413014","DOI":"10.1177\/10760296241301402","volume":"30","author":"C Cheng","year":"2024","unstructured":"Cheng C, Hua J, Xiong L. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost United States. 2024;30:10760296241301402. https:\/\/doi.org\/10.1177\/10760296241301402.","journal-title":"Clin Appl Thromb Hemost United States"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00882-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00882-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00882-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:51:52Z","timestamp":1786661512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00882-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00882-5","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"74"}}